Re: Irwin Goldstein, MD
BigKNY,
Isn't it a shame when we become so jaded that we don't know who we can believe at times.
As you can see from these news releases Dr IG has his hand in many a pocket but not VIVUS'. No it doesn't have to make his statements incorrect but it should make one wonder. He can not be unbiased. As an investment adviser said on CNBC just yesterday, "Whoever's bread we eat, his song we sing"! Be sure to read to the end.
June 26, 1997-- MacroChem announced that prominent urologist and leading
impotence specialist, Dr. Harin Padma-Nathan joins Irwin Goldstein,
M.D., Professor of Urology, Boston University School of Medicine, David
Ferguson, Ph.D., M.D., consultant in clinical development project
management, and Stephen Riggi, Ph.D., MacroChem's VP of Operations, as
part of the team assigned to develop MacroChem's topical gel for
erectile dysfunction.
April 10, 1997-- MacroChem announced that it is accelerating the product
development program of a topical gel containing alprostadil and SEPA,
for the treatment of erectile dysfunction (impotence). This decision is
based on the promising results of the ongoing Phase I/II study conducted
by Kevin McVary, M.D. at Northwestern University. Irwin Goldstein, M.D.,
Professor of Urology at the Boston University School of Medicine, will
assist with the scientific and clinical direction of the program. He
specializes in the research, diagnosis and treatment of erectile
dysfunction, and has published over 150 scientific papers in this area.
Dr. Goldstein played a role in the investigation and development of
other products for the treatment of erectile dysfunction including
Pharmacia & Upjohn's Caverject, Pfizer's Viagra and Zonagen's Vasomax |
